Evidence map›Paper›PMID 42723253›Full record

ArticleChemMedChem2026

Synthesis and Assessment of the Enantioselectivity in Antitumor Activity of a Library of Novel Chiral Flavone Derivatives.

Cláudia Pinto, Flávia Barbosa, João Machado, Andrea Cunha, Patrícia M A Silva, Mariangela Agamennone, Hassan Bousbaa, Honorina Cidade, Odília Queirós, Maria Elizabeth Tiritan

Abstract read
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cláudia PintoLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.ORCID https://orcid.org/0000-0002-7292-1517
Flávia BarbosaUCIBIO - Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), Gandra PRD, Portugal.ORCID https://orcid.org/0000-0002-2920-0941
João MachadoLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.ORCID https://orcid.org/0009-0001-8632-4975
Andrea CunhaUNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS-CESPU), Gandra PRD, Portugal.ORCID https://orcid.org/0000-0002-3012-1079
Patrícia M A SilvaUCIBIO - Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), Gandra PRD, Portugal.ORCID https://orcid.org/0000-0002-0694-7321
Mariangela AgamennoneDepartment of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Chieti CH, Italy.ORCID https://orcid.org/0000-0001-5198-0051
Hassan BousbaaUCIBIO - Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), Gandra PRD, Portugal.ORCID https://orcid.org/0000-0002-4006-5779
Honorina CidadeLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.ORCID https://orcid.org/0000-0003-0715-1779
Odília QueirósUCIBIO - Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), Gandra PRD, Portugal.
Maria Elizabeth TiritanLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.ORCID https://orcid.org/0000-0003-3320-730X

Funding

Cooperativa de Ensino Superior Politécnico e Universitário FlavScreen_GI2-CESPU-2023Cooperativa de Ensino Superior Politécnico e Universitário GI2-CESPU-2025Fundação para a Ciência e a Tecnologia 2022.12419.BDFundação para a Ciência e a Tecnologia LA/P/0140/2020Fundação para a Ciência e a Tecnologia UID/04423/2025
6 · The paper itself

Abstract

Nature represents a rich source of bioactive compounds, with flavones emerging as privileged scaffolds owing to their multiple biological activities. Their antitumor potential arises from their ability to modulate pathways implicated in cancer progression and multidrug resistance, but structural modifications are often required to improve their pharmacokinetic properties and target selectivity. Incorporating chiral moieties, such as amino acids, may improve their potency and selectivity. Herein, we report the stereoselective synthesis of 32 new chiral derivatives of flavones (CDFs) obtained by coupling four commercial flavones with the enantiomerically pure amino esters and amino acids of tryptophan and tyrosine. Overall, the amino ester derivatives showed greater antiproliferative activity than their parent flavones against four cancer cell lines. 6HF-DTrp (14) and 7HF-DTrp (18) demonstrated micromolar equipotent inhibition with IC50 <21 µM against all cell lines. Most CDFs preferentially affected cancer cells over nontumor HPAEpiC cells, particularly 7HF-DTrp (18), which displayed selectivity indices above 6. Metabolic assays exposed heterogeneous effects on glucose consumption and lactate production, suggesting that CDF-induced cytotoxicity depends on the metabolic flexibility of each tumor phenotype rather than a universal mechanism. Furthermore, in vitro and in silico studies suggest potential P-glycoprotein (P-gp) inhibitory activity for 6HF-DTrp (14) and 7HF-DTrp (18).

Indexed as

Antineoplastic AgentsFlavonesCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMolecular StructureStereoisomerismStructure-Activity RelationshipAntineoplastic AgentsFlavonesantitumor activityapoptosiscellular metabolismchiral flavonesmultidrug resistance

Identifiers

PMID42723253
PMCPMC13562834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.